Zusammenfassung
Mit Certolizumab pegol (CDP870) steht seit Oktober 2009 ein neuer TNF-α-Blocker zur Behandlung der rheumatoiden Arthritis zur Verfügung. Durch eine Modifizierung des Antikörperfragments durch das Anhängen von Polyethylenglykol (PEG) konnte im Tierversuch ein besseres Eindringen in entzündliches Gewebe nachgewiesen werden. In zwei individuellen Patientenkasuistiken konnte bei therapierefraktären Arthritiden eine Remission unter dem pegylierten Certolizumab erreicht werden.
Abstract
Certolizumab pegol is a new anti-TNF-alpha inhibitor which has been approved for the treatment of rheumatoid arthritis since October 2009. Due to the modification of the antibody fragment by the adherence of polyethylene glycol (PEG) a sufficient distribution in inflammatory tissue was found in animal experiments. In two individual case reports a remission of therapy refractive arthritis was achieved by administration of certolizumab pegol.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Genovese MC, Bathon JM, Martin RW et al (2002) Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 46(6):1443–1450
Elliott MJ, Maini RN, Feldmann M et al (1994) Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344(8930):1105–1110
Maini RN, Breedveld FC, Kalden JR et al (1998) Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41(9):1552–1563
Maini R, St Clair EW, Breedveld F et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354(9194):1932–1939
Lipsky PE, Heijde DM van der, St Clair EW et al; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group(2000).Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 343(22):1594–1602
Moreland LW, Baumgartner SW, Schiff MH et al (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337(3):141–147
Weinblatt ME, Kremer JM, Bankhurst AD et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340(4):253–259
Weinblatt ME, Keystone EC, Furst DE et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48(1):35–45
Furst DE, Schiff MH, Fleischmann RM et al (2003) Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 30(12):2563–2571
Keystone EC, Kavanaugh AF, Sharp JT et al (2004) Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 50(5):1400–1411
Sandborn WJ, Feagan BG, Stoinov S et al (2007) Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med 357(3):228–238
Choy EH, Hazleman B, Smith M et al (2002) Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 41(10):1133–1137
Keystone E, Heijde D, Mason D Jr et al (2008) Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 58(11):3319–3329
Smolen JS, Landewé RB, Mease PJ et al (2009) Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. Ann Rheum Dis 68:797–804
Arnett FC, Edworthy SM, Bloch DA et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31(3):315–324
Palframan R, Vugler A, Moore A et al (2007) In vivo biofluorescence imaging of Alexa 680-labeled certolizumab pegol and adalimumab accumulation in the inflamed paws of mice with collagen-induced arthritis compared with uninflamed tissue. Ann Rheum Dis 66:588
Interessenkonflikt
Der korrespondierende Autor weist auf folgende Beziehung hin: Kostenübernahme (Reise) EULAR Rom 2010 durch UCB.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Schmeiser, T., Müller- Ladner, U. Therapie mit Certolizumab pegol bei Patienten mit destruierender Arthritis. Z. Rheumatol. 69, 653–656 (2010). https://doi.org/10.1007/s00393-010-0629-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00393-010-0629-x